Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)
Sweden · Delayed Price · Currency is SEK 61.00
+1.00 (1.67%)
At close: Jun 12, 2026
Infant Bacterial Therapeutics AB Earnings Call Transcripts
Fiscal Year 2024
-
A large study in premature infants showed no statistical significance for primary endpoints (NEC and feeding tolerance), but demonstrated a significant 27% reduction in all-cause mortality with a strong safety profile. Regulatory submission is planned, leveraging the robust mortality benefit and existing precedents for approval based on secondary endpoints.